Philadelphia-based Topaz Pharmaceuticals has raised $20 million in Series A financing from Aisling Capital and Fidelity Biosciences. The funds will be used to help Topaz complete clinical trials of the company's new prescription medicine to fight head lice, which are becoming more resistant to some traditional treatments. The funding will also be used to prepare the product for market.
- check out the release from Topaz
ALSO: Cambridge, MA-based Merrimack Pharmaceuticals has raised $35 million of an $80 Series F financing round. Investors in the round were not disclosed. Report
PLUS: Evalve, a developer devices for the percutaneous repair of cardiac valves, has completed a $60 million Series D financing. Release